Last reviewed · How we verify
SC411
SC411 is a small molecule that targets the SGLT2 receptor.
SC411 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | SC411 |
|---|---|
| Also known as | Docosahexaenoic acid (DHA) |
| Sponsor | Micelle BioPharma Inc |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, SC411 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly useful for the treatment of type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of diabetic ketoacidosis
Key clinical trials
- A Sickle CEll Disease ComplicatioN Trial (PHASE3)
- Dose-Finding Study of SC411 in Children With Sickle Cell Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |